| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Tumor necrosis factor receptor superfamily member 10C; Antagonist decoy receptor for TRAIL/Apo-2L; Decoy TRAIL receptor without death domain; Decoy receptor 1; DcR1; Lymphocyte inhibitor of TRAIL; TNF-related apoptosis-inducing ligand receptor 3; TRAIL receptor 3; TRAIL-R3; TRAIL receptor without an intracellular domain; CD263; TNFRSF10C; DCR1; LIT; TRAILR3; TRID; UNQ321/PRO366 |
| Clonality | |
| Form | Liquid |
| Host | |
| Immunogen | E. coli - derived recombinant human TNFRSF10C (Ala26-Glu152). |
| Isotype | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target |
Overview
Anti-Human TNFRSF10C Polyclonal Antibody targets TNFRSF10C (Tumor necrosis factor receptor superfamily member 10C). Frequently used across ELISA, IHC, WB workflows, depending on experimental design and sample type. This antibody is suited for workflows commonly used in Immunology & Inflammation research.
Also known as: Tumor necrosis factor receptor superfamily member 10C, TRAIL receptor without an intracellular domain, TNF-related apoptosis-inducing ligand receptor 3, Decoy TRAIL receptor without death domain, Antagonist decoy receptor for TRAIL/Apo-2L, Lymphocyte inhibitor of TRAIL, Decoy receptor 1, TRAIL receptor 3, TRAIL-R3, UNQ321/PRO366.
Target biology
TNFRSF10C (Tumor necrosis factor receptor superfamily member 10C) encodes a receptor or receptor subunit involved in sensing extracellular or cell-surface cues and relaying signals to intracellular pathways. Receptor availability at the cell surface and activation state can vary with differentiation and stimulation conditions. Common alternative names and symbols used in the literature include: TRAIL receptor without an intracellular domain, TNF-related apoptosis-inducing ligand receptor 3, Decoy TRAIL receptor without death domain, Antagonist decoy receptor for TRAIL/Apo-2L, Lymphocyte inhibitor of TRAIL, Decoy receptor 1, TRAIL receptor 3, TRAIL-R3, UNQ321/PRO366, TRAILR3. Based on the annotated name/class, the target is most often associated with plasma membrane and/or intracellular membranes localization, though this can vary by model system.
How this antibody helps
As a polyclonal reagent, this antibody can provide strong sensitivity through recognition of multiple epitopes on the target. For best performance, interpret signal in the context of appropriate biological controls and orthogonal readouts when available.
Antigen / immunogen context
E. coli - derived recombinant human TNFRSF10C (Ala26-Glu152).
Recommended experimental notes
- Titrate the antibody to optimize signal-to-noise for your specific sample type and detection system.
- Use appropriate positive and negative controls (e.g., target-high vs target-low samples, KO/KD where available).
- For Western blotting, use fresh protease (and phosphatase, if relevant) inhibitors and confirm the primary band at the expected molecular weight; additional bands may reflect isoforms or processing.
- For IHC, optimize fixation and antigen retrieval (buffer/pH/heat) and include an isotype/secondary-only control to assess background.
- For ELISA, optimize capture/detection pairing and run a standard curve in matrix-matched diluent when possible.
Additional notes
For research use only
For research use only. Not for diagnostic procedures.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.